Combination strategies—such as using metformin alongside next-generation AR pathway inhibitors and immune checkpoint blockade, or learning from therapeutic successes in other tumor types (e.g., applying sotorasib in LKB1-deficient settings)—offer tangible hope, particularly for patients with aggressive or refractory disease marked by high levels of STAT3 or CREB activity. This evidence concerns the gene STAT3 and neoplasm.